Dr. Reddy’s Biologics License Application for its proposed biosimilar rituximab candidate DRL_RI has been accepted for a substantive review by the Food and Drug Administration. This closely follows ...
The Korea Herald reports that Celltrion is on track to file applications for U.S. FDA approval for its rituximab and trastuzumab biosimilars by June. According to the article (and as previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback